Ariadna Acedo Terrades

Ariadna Acedo Terrades

Auto-generated profile, based on publicly available information

Ariadna Acedo Terrades

Nanomaterials in Health Laboratory, Swiss Federal Laboratories for Materials Science and Technology (Empa), 9014 St. Gallen, Switzerland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2024 in medRxiv
Verified
Preprint
Open access
PDF file
AAAriadna Acedo-Terrades
Ariadna Acedo-Terrades
ARAlejo Rodriguez-Vida
Alejo Rodriguez-Vida
OBOscar Buisan
Oscar Buisan
MTMarta Bodalo Torruella
Marta Bodalo Torruella
MGMaria Gabarrós
Maria Gabarrós
JBJoaquim Bellmunt
Joaquim Bellmunt
Muscle-invasive bladder cancer (MIBC) is associated with poor predictability of response to cisplatin-based neoadjuvant chemotherapy (NAC). Consequently, the benefit of NAC remains unclear for many patients due to the lack of reliable biomarkers. In order to identify biomarkers and build an integrated and accurate model to predict NAC response, we conducted a comprehensive transcriptomic and genomic profiling on 100 MIBC patient tumors. Our analysis identified 602 differentially expressed genes between responders and non responders. From these, we derived the Top10up and Top10dn gene signatures. We also identified a set of genes related to keratinization (KRT), extracellular matrix (ECM) and cell cycle regulation (CELL CYCLE REG) that were strongly associated with response. Additionally, we found a Wnt-related signature (WNT) significantly associated with non response. Genomic analysis revealed that mutations in DNAH8, DNAH6 or DNAH10 (DNAHalt) and deletions in KDM6A (KDM6Adel) correlated significantly with chemotherapy resistance. Using our comprehensive molecular analysis as a backbone, we developed different machine learning (ML) models, based on the Xgboost (XGB) approach. The transcriptomics-only model (XGB-R) matched the performance of the combined model (XGB-RW; AUC=0.85). The relative ease of sample collection for transcriptomic data, along with the external validation, make it a promising candidate for clinical translation. To ensure robustness and broader applicability, external validation in larger, more diverse cohorts is necessary. To facilitate this, our most predictive ML models have been made publicly available via GitHub. Statement of significance: We present XGB-R, a robust validated machine-learning model using transcriptomic features to predict neoadjuvant chemotherapy response in muscle-invasive bladder cancer with high accuracy (AUC=0.85), being a candidate for clinical translation.

19 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SOSergio Vazquez Montes de Oca
Sergio Vazquez Montes de Oca
ATAriadna Acedo Terrades
Ariadna Acedo Terrades
JMJose F Carreño Martinez
Jose F Carreño Martinez
PKPhilipp Kirchner
Philipp Kirchner
TÖTiit Örd
Tiit Örd
MMMaría Rodríguez Martínez
María Rodríguez Martínez
Background: Single-cell transcriptomics has revealed extensive macrophage heterogeneity in atherosclerotic plaques, but how disease-associated programs reshape cellular identity remains unclear. Connecting macrophage states to these molecular changes could help identify candidate routes through which macrophages contribute to inflammation and fibrosis. Methods: We developed a computational method combining optimal transport, RNA velocity and comparative program analysis across 34,533 monocytes and macrophages from seven human cohorts. Optimal transport quantified all 15 pairwise relationships among six macrophage states, and target-association gradients supported source- and destination-program comparisons across 11 relationships. Expression contrasts were calculated within libraries and source subtypes. Robustness was assessed through resampling, cohort omission and held-out-gene analyses. Paired RNA and protein measurements provided complementary molecular evidence, and patient-label permutation tests evaluated exploratory clinical associations in 18 patients. We also applied the method to an independent human liver dataset. Results: Scavenging and inflammatory macrophages formed the closest transcriptional pair in the full atlas and every cohort-omission analysis. Scavenging macrophages retained selected source features alongside inflammatory programming, whereas fibrotic association coincided with attenuation of the broader scavenging signature. This signature showed a lower change along fibrotic than inflammatory association in all 19 matched libraries. Protein measurements corroborated selected changes and revealed coexisting scavenging and activation features within individual cells. Symptomatic patients had a higher fraction of monocytes with strong inflammatory association than asymptomatic patients (median difference, 13.0 percentage points; unadjusted one-sided permutation p = 0.0017). Analysis of 8,536 liver mononuclear phagocytes further resolved contrasting source-marker responses along scar-associated macrophage association. Conclusions: These findings connect macrophage heterogeneity to selective identity remodeling across disease-associated states. Integrating population relationships with RNA, protein and clinical measurements provides a strategy for prioritizing candidate pathogenic routes and their associated molecular programs for functional investigation.